Vorsetuzumab

Vorsetuzumab (also known as MORAb-003) is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Morphotek, a subsidiary of Eisai Co..

Mechanism of Action[edit | edit source]

Vorsetuzumab is a humanized monoclonal antibody that targets folate receptor α (FRα). FRα is overexpressed in several types of human cancers, including ovarian cancer, lung cancer, and endometrial cancer. By binding to FRα, vorsetuzumab inhibits the growth of cancer cells that overexpress this receptor.

Clinical Trials[edit | edit source]

Vorsetuzumab has been evaluated in several clinical trials for its efficacy in treating various types of cancer. In a Phase II trial for recurrent platinum-sensitive ovarian cancer, vorsetuzumab showed promising results with a manageable safety profile. However, further studies are needed to confirm these findings and determine the optimal dosing regimen.

Side Effects[edit | edit source]

As with all medications, vorsetuzumab may cause side effects. Common side effects include fatigue, nausea, and vomiting. Serious side effects may include allergic reactions, pulmonary edema, and neutropenia. Patients should discuss potential side effects with their healthcare provider before starting treatment with vorsetuzumab.

Future Directions[edit | edit source]

Research is ongoing to further understand the potential of vorsetuzumab in treating various types of cancer. Future studies may explore the use of vorsetuzumab in combination with other therapies, as well as its efficacy in treating other types of cancer that overexpress FRα.